Integra LifeSciences Holdings Corp. (NASDAQ:IART)’s share price hit a new 52-week high during trading on Thursday . The stock traded as high as $80.63 and last traded at $80.44, with a volume of 91,216 shares traded. The stock had previously closed at $79.26.

Several brokerages have recently commented on IART. Zacks Investment Research raised shares of Integra LifeSciences Holdings Corp. from a “hold” rating to a “buy” rating and set a $85.00 price target on the stock in a research report on Tuesday, June 28th. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $85.00 price target on shares of Integra LifeSciences Holdings Corp. in a research report on Friday, June 24th. Barclays PLC increased their price target on shares of Integra LifeSciences Holdings Corp. from $74.00 to $77.00 and gave the stock an “equal weight” rating in a research report on Thursday, June 2nd. Jefferies Group reaffirmed a “buy” rating on shares of Integra LifeSciences Holdings Corp. in a research report on Thursday, April 28th. Finally, Oppenheimer Holdings Inc. reaffirmed a “buy” rating on shares of Integra LifeSciences Holdings Corp. in a research report on Thursday, April 28th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $79.00.

The stock’s market cap is $3.03 billion. The company’s 50 day moving average is $76.41 and its 200 day moving average is $67.74.

Integra LifeSciences Holdings Corp. (NASDAQ:IART) last announced its earnings results on Wednesday, April 27th. The company reported $0.74 EPS for the quarter, topping the consensus estimate of $0.73 by $0.01. The firm earned $236.80 million during the quarter, compared to the consensus estimate of $230.66 million. The business’s revenue was up 1.3% compared to the same quarter last year. During the same quarter last year, the business earned $0.76 EPS. Equities research analysts forecast that Integra LifeSciences Holdings Corp. will post $3.44 EPS for the current fiscal year.

In related news, Director Stuart Essig sold 104,390 shares of Integra LifeSciences Holdings Corp. stock in a transaction on Wednesday, April 27th. The shares were sold at an average price of $70.15, for a total value of $7,322,958.50. Following the transaction, the director now owns 1,064,709 shares in the company, valued at approximately $74,689,336.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Christian S. Schade sold 7,829 shares of Integra LifeSciences Holdings Corp. stock in a transaction on Tuesday, May 3rd. The stock was sold at an average price of $70.42, for a total transaction of $551,318.18. Following the completion of the transaction, the director now owns 18,550 shares in the company, valued at approximately $1,306,291. The disclosure for this sale can be found here.

Other hedge funds and institutional investors recently bought and sold shares of the company. GSA Capital Partners LLP increased its position in Integra LifeSciences Holdings Corp. by 160.4% in the fourth quarter. GSA Capital Partners LLP now owns 34,122 shares of the company’s stock valued at $2,313,000 after buying an additional 21,020 shares during the last quarter. American Century Companies Inc. increased its position in Integra LifeSciences Holdings Corp. by 1.9% in the fourth quarter. American Century Companies Inc. now owns 114,602 shares of the company’s stock valued at $7,768,000 after buying an additional 2,163 shares during the last quarter. Sei Investments Co. increased its position in Integra LifeSciences Holdings Corp. by 57.4% in the fourth quarter. Sei Investments Co. now owns 75,002 shares of the company’s stock valued at $5,084,000 after buying an additional 27,347 shares during the last quarter. Rhumbline Advisers increased its position in Integra LifeSciences Holdings Corp. by 6.6% in the fourth quarter. Rhumbline Advisers now owns 45,298 shares of the company’s stock valued at $3,070,000 after buying an additional 2,820 shares during the last quarter. Finally, Boston Partners increased its position in Integra LifeSciences Holdings Corp. by 5.4% in the fourth quarter. Boston Partners now owns 458,516 shares of the company’s stock valued at $31,078,000 after buying an additional 23,393 shares during the last quarter.

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing and marketing of surgical implants and medical instruments. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery. Its segments include Specialty Surgical Solutions, which offers products, including specialty surgical instrumentation for a range of specialties.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.